MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

Science

Volumn 316, Issue 5827, 2007, Pages 1039-1043

  Engelman, Jeffrey A ^a,b,c   Zejnullahu, Kreshnik ^d   Mitsudomi, Tetsuya ^e   Song, Youngchul ^b,c   Hyland, Courtney ^f   Joon, Oh Park ^d   Lindeman, Neal ^f   Gale, Christopher Michael ^c   Zhao, Xiaojun ^d   Christensen, James ^g   Kosaka, Takayuki ^e   Holmes, Alison J ^d   Rogers, Andrew M ^d   Cappuzzo, Federico ^h   Mok, Tony ⁱ   Lee, Charles ^f   Johnson, Bruce E ^d   Cantley, Lewis C ^b,c   Jänne, Pasi A ^d  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

CANCER; DISEASE TREATMENT; DRUG RESISTANCE; RESPIRATORY DISEASE; TUMOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; RECEPTOR GENE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE AMPLIFICATION; HUMANS; INDOLES; LUNG NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-3; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONES;

EID: 34249075147     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1141478     Document Type: Article

References (24)

1. B. J. Druker et al., N. Engl. J. Med. 344, 1038 (2001).
2. G. D. Demetri et al., N. Engl. J. Med. 347, 472 (2002).
3. J. G. Paez et al., Science 304, 1497 (2004).
4. T. J. Lynch et al., N. Engl. J. Med. 350, 2129 (2004).
5. T. Kosaka et al., Clin. Cancer Res. 12, 5764 (2006).
6. M. N. Balak et al., Clin. Cancer Res. 12, 6494 (2006).
7. J. A. Engelman et al., Proc. Natl. Acad. Sci. U.S.A. 102, 3788 (2005).
8. J. A. Engelman et al., J. Clin. Invest. 116, 2695 (2006).
9. N. V. Sergina et al., Nature 445, 437 (2007).
10. Materials and methods are available as supporting material on Science Online.
11. G. A. Smolen et al., Proc. Natl. Acad. Sci. U.S.A. 103, 2316 (2006).
12. C. T. Miller et al., Oncogene 25, 409 (2006).
13. J. G. Christensen et al., Cancer Res. 63, 7345 (2003).
14. K. M. Weidner et al., Nature 384, 173 (1996).
15. T. Mukohara et al., Clin. Cancer Res. 11, 8122 (2005).
16. M. C. Heinrich et al., J. Clin. Oncol. 24, 4764 (2006).
17. M. Debiec-Rychter et al., Gastroenterology 128, 270 (2005).
18. A. Hochhaus et al., Leukemia 16, 2190 (2002).
19. N. J. Donato et al., Blood 101, 690 (2003).
20. T. Kosaka et al., Cancer Res. 64, 8919 (2004).
21. T. Shibata et al., Clin. Cancer Res. 11, 6177 (2005).
22. A. Inoue et al., J. Clin. Oncol. 24, 3340 (2006).
23. F. M. Yakes et al., Cancer Res. 62, 4132 (2002).
24. We thank M. Begley for providing the lentiviral expression vector, E. Fox for MET sequencing, and K. Cichowski and D. E. Fisher for helpful discussions. This work was supported by grants from the National Institutes of Health 1K12CA87723-01 (P.A.J.), RO1CA114465-01 (B.E.J. and P.A.J.), RO1-CA111560 (C.L.), NIH GM41890 (L.C.C.) and PO1 CA089021 (L.C.C.), the National Cancer Institute K08CA120060-01 (J.A.E.), the National Cancer Institute Lung SPORE P20CA90578-02 (B.E.J.), the American Cancer Society RSG-06-102-01 (P.A.J. and J.A.E.), and by the American Association for Cancer Research, the International Association for the Study of Lung Cancer (J.A.E.) and the Italian Association for Cancer Research (F.C.). P.A.J. and B.E.J. are part of a pending patent application on EGFR mutations.